Stay updated with breaking news from James Chambers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Deena Beasley (Reuters) - The future of Aduhelm, Biogen Inc's controversial and expensive Alzheimer's drug, may hinge on a decision due this week f...
Sec. Becerra’s directive came two days before CMS is set to release its draft guidance on whether Medicare will cover Aduhelm.
The FDA has faced sharp criticism for approving Aduhelm even though clinical trials exposed serious safety risks.
Decision looms that could determine fate of Alzheimer’s drug
Federal officials are wrestling with a decision that could go a long way toward determining the future of the new Alzheimer's drug Aduhelm and whether significant numbers of patients use it.